Amgen's Repatha (evolocumab) antibody against PCSK9 is approved just one month after Sanofi's Praluent (alirocumab). More combination treatments continue to reach the market, including Orkambi (ivacaftor and lumacaftor) for cystic fibrosis and Entresto (sacubitril and valsartan) for congestive heart failure. In the coming months, the US Food and Drug Administration is slated to make decisions on several biosimilars, including the first monoclonal antibody (in the US). Also coming before the FDA will be the first and somewhat controversial oncolytic virus.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline: 3Q15. Nat Biotechnol 33, 1126 (2015). https://doi.org/10.1038/nbt.3405
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3405
